Xencor (NASDAQ:XNCR) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Xencor (NASDAQ:XNCR) from a strong sell rating to a hold rating in a research note released on Saturday morning.

Several other brokerages have also weighed in on XNCR. Wedbush lifted their price objective on Xencor from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday. Truist Financial reduced their target price on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Royal Bank Of Canada lifted their price target on shares of Xencor from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Thursday. Zacks Research raised shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, Cantor Fitzgerald increased their price objective on shares of Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research note on Thursday. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $24.86.

Xencor Stock Performance

Shares of XNCR opened at $20.81 on Friday. The company has a 50-day simple moving average of $15.69 and a 200-day simple moving average of $13.37. Xencor has a 52 week low of $6.92 and a 52 week high of $21.96. The firm has a market capitalization of $1.55 billion, a P/E ratio of -9.59 and a beta of 0.85.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.51. The firm had revenue of $51.22 million for the quarter, compared to analyst estimates of $18.89 million. Xencor had a negative return on equity of 28.66% and a negative net margin of 155.59%.The company’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.41) earnings per share. As a group, equities analysts forecast that Xencor will post -2.99 earnings per share for the current year.

Institutional Investors Weigh In On Xencor

A number of hedge funds have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new position in Xencor in the fourth quarter valued at about $81,000. Tower Research Capital LLC TRC increased its holdings in shares of Xencor by 118.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 3,018 shares in the last quarter. E Fund Management Co. Ltd. bought a new position in shares of Xencor in the second quarter valued at approximately $79,000. Norges Bank bought a new position in shares of Xencor in the fourth quarter valued at approximately $175,000. Finally, Prelude Capital Management LLC acquired a new position in shares of Xencor in the 3rd quarter worth approximately $139,000.

Xencor News Roundup

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Quarterly results beat expectations: Xencor reported a second-quarter loss of $0.29 per share, narrower than the $0.80–$0.82 consensus estimate and better than the $0.41 loss recorded a year earlier. Revenue reached approximately $51.2 million, well above the roughly $18.9 million analyst forecast and up 17.4% year over year. Xencor Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised valuation expectations: Wedbush increased its price target from $26 to $30 and maintained an “outperform” rating. Cantor Fitzgerald also raised its target from $43 to $44 while keeping an “overweight” rating, signaling substantial potential upside based on their estimates. Analyst Price Target Updates
• Positive Sentiment: RBC Capital reaffirmed its “buy” rating for Xencor, providing additional support for the bullish analyst view following the earnings release. RBC Capital Sticks to Their Buy Rating for Xencor
• Neutral Sentiment: Brokerage consensus remains cautious: Despite several bullish individual ratings, the overall analyst consensus is “hold,” suggesting that expectations for Xencor remain mixed. Xencor Given Consensus Rating of Hold
• Negative Sentiment: Profitability remains a risk: Xencor continues to report net losses, and analysts forecast a full-year loss. The company’s negative margins mean the stock remains dependent on clinical, commercial, and partnership progress to justify its valuation.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.